Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 5,903 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

NCT02348008
View directory record Official record
Conditions
Clear Cell Renal Carcinoma
Interventions
MK-3475, Bevacizumab
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778
View directory record Official record
Conditions
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Phase 4 Interventional Results available

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

NCT04650217
View directory record Official record
Conditions
Depressive Disorder
Interventions
Carbidopa/levodopa, Placebo, Exercise training, Control
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional

A Megastudy of Single-Session Interventions for Depression

NCT06856668
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Behavioral Activation (Action Brings Change Project 10-Minute Version), Mindful Acceptance, Moral Elevation, Mindful Attention Skills, 5 Habits to Beat Depression, Interactive Cognitive Reappraisal, Expressive Writing (AI-supported), Inner Child Healing Walk, Savoring Strategies, Personalized Intervention Recommender, Dialectical Behavioral Therapy Skills, All about Trout, Reframing Negative Thoughts
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7,505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

NCT03195699
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions
TTI-101
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Completed No phase listed Observational

The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation

NCT01148914
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Inflammatory biomarkers
Other
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Level Up! (The Combined and Independent Effects of Exercise Training and Dietary Enhancement on Cardiometabolic Health in Adolescents With Obesity)

NCT06848478
View directory record Official record
Conditions
Obesity
Interventions
Exercise Intervention, Nutritional Intervention
Behavioral
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Vestibular Balance Therapy Intervention for Children

NCT05741515
View directory record Official record
Conditions
Vestibulocochlear Nerve Diseases, Vestibular Disorder, Bilateral Vestibular Loss
Interventions
Vestibular Balance Therapy, Sham Intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

NCT05356117
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Resistance Training (RT) and Protein Supplementation (PS), Resistance Training (RT), Attention Control (AC
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

NCT00550017
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Epofolate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Combining Exercise and Cognitive Training to Improve Everyday Function

NCT01603784
View directory record Official record
Conditions
Effect of Exercise on Cognitive Function
Interventions
Intensive Exercise, Home Exercise, Cognitive Training, Health Education
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 26, 2026, 10:09 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

NCT05363293
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Interventions
AL001, Placebo
Drug · Other
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 26, 2026, 10:09 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Nalbuphine ER in Participants With Hepatic Impairment

NCT04020016
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Nalbuphine ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Active, not recruiting Not applicable Interventional

Behavioral Economic and Wellness-based Approaches for Reducing Alcohol Use and Consequences Among Emerging Adults

NCT04776278
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Brief Alcohol Intervention (BAI), Substance-free Activity Session (SFAS), Relaxation Training (RT), Education Control
Behavioral · Other
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 29 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 26, 2026, 10:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Depression, Cytokines and Pancreatic Cancer

NCT00582699
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
assessment interview and blood draw
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Cardiometabolic Health Intervention Using Movement-to-Music Exercise

NCT05606432
View directory record Official record
Conditions
Cardiometabolic Risk Factors in Adult Wheelchair Users
Interventions
Instructor-led, one-on-one M2M exercise group, Self-guided control with pre-recorded standard exercise videos
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Fluid Lavage of Open Wounds

NCT00788398
View directory record Official record
Conditions
Open Fracture Wounds
Interventions
Saline Solution, Soap solution, Gravity Flow Irrigation, Low Pressure Irrigation, High Pressure
Procedure
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
14 Years to 85 Years
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

NCT01954316
View directory record Official record
Conditions
Advanced Cancer
Interventions
CFI-400945
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pulse Biomarker Discovery

NCT04887584
View directory record Official record
Conditions
Body Weight
Interventions
Control diet, Low Pulse diet, High Pulse diet
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

NCT01438749
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO4917838, diazepam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 10:09 AM EDT